Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Cirrhosis from fatty liver disease isn't just an older adult problem anymore. A new study found that adults under 50 with type 2 diabetes and a high genetic risk score are significantly more likely to develop early-onset MASLD cirrhosis — and standard screening tools like the FIB-4 index are missing nearly a third of these cases because they factor in age.
Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly showing up in adults under 50, and a new multicenter study suggests current screening tools aren't catching it. Researchers analyzed 2,395 adults with biopsy-confirmed MASLD and found that 22.6% of cirrhosis cases occurred in patients younger than 50 — a group with a distinct risk profile driven by genetics and metabolic disease.
The culprit? A combination of type 2 diabetes, obesity, and a high genetic risk score (based on variants in PNPLA3, TM6SF2, and HSD17B13) dramatically raises the odds of early-onset cirrhosis. Meanwhile, the widely used FIB-4 index — which incorporates age into its calculation — flagged fewer than expected cases, leaving younger patients in a diagnostic blind spot.
Key Takeaways:
Why it matters: As MASLD becomes more prevalent in younger populations, relying on age-weighted tools risks leaving high-risk patients undiagnosed until it's too late. Experts are calling for age-aware screening pathways that combine metabolic risk factors, genetic testing, and direct liver stiffness measurement for younger adults with diabetes or severe obesity.